A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies

  • End date
    May 11, 2027
  • participants needed
  • sponsor
    CRISPR Therapeutics AG
Updated on 11 December 2020
diffuse large b-cell lymphoma
b-cell lymphoma
large b-cell lymphoma


This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.


The study may enroll approximately 45 subjects in total.

Treatment CTX130
Clinical Study IdentifierNCT04502446
SponsorCRISPR Therapeutics AG
Last Modified on11 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: T-Cell Lymphoma or Non-Hodgkin's Lymphoma or Lymphoma?
Do you have any of these conditions: t cell lymphoma or Lymphoma or Non-Hodgkin's Lymphoma or T-Cell Lymphoma?
Do you have any of these conditions: Lymphoma or t cell lymphoma or Non-Hodgkin's Lymphoma or T-Cell Lymphoma?
Do you have any of these conditions: Lymphoma or T-Cell Lymphoma or Non-Hodgkin's Lymphoma or t cell lymphoma?
Do you have any of these conditions: t cell lymphoma or Non-Hodgkin's Lymphoma or Lymphoma or T-Cell Lymphoma?
Age 18 years and body weight 60 kg
Confirmed diagnosis of a T cell malignancy or Diffuse Large B-Cell Lymphoma (DLBCL)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Adequate renal, liver, cardiac, and pulmonary organ function
Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX130 infusion

Exclusion Criteria

Prior allogeneic stem cell transplant (SCT)
Prior treatment with any anti-CD70 targeting agents
History of certain central nervous system (CNS), cardiac or pulmonary conditions
Active HIV, hepatitis B virus or hepatitis C virus infection
Previous or concurrent malignancy, except treated with curative approach not requiring systemic therapy and in remission for >12 months, or any other localized malignancy with low risk of developing into metastatic disease
Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy
Prior solid organ transplantation
Pregnant or breastfeeding females
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet